March 15, 2018
Last week was the annual 2018 meeting of the American Hepatobiliary-PancreaticoBiliary association held in Miami Beach at the Lowe’s Hotel. Altogether 350 lectures and poster sessions; with 10 dedicated NanoKnife. Overall it was rather prosaic with many discussions of marginal relevancy but a few stood out. The Pancreatic meetings focused primarily on prediction of outcome and complication reduction. No new chemotherapy advances were revealed; but some disappointment surrounded excitement by some national leaders about several ongoing trials in the re-configuring of the same 4 agents. Immunotherapy continues to impact 5% of PanCan patients, but induced cell membrane changes stimulating various arms of the immune system may significantly increase that number potentially to 20%!
8 January, 2018 By Robert B Donoway M.D., F.A.C.S.
World Class Cancer Care Personalized For You
I have written numerous times that in order for Nanoknife ablation of the Pancreas to be successful the probes must be placed entirely around the tumor. This requires 3D planning and multi-planar positioning.
In the attached photo of a Pancreatic Duct Adenocarcinoma (PDAC)...